Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 2/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.37 |
| ▸ | HTR7 | P34969 | 3/20 | 0.37 |
| ▸ | HTR1A | P08908 | 1/20 | 0.37 |
| ▸ | HRH3 | Q9Y5N1 | 4/20 | 0.36 |
| ▸ | HTR2A | P28223 | 2/20 | 0.36 |
| ▸ | HTR6 | P50406 | 2/20 | 0.36 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21160630 | 0.93 | CYP1A2 (0.49) | CYP1A2KDM4EMAPTMEN1KMT2A | |
| SCHEMBL13888250 | 0.85 | CYP1A2 (0.42) | CYP1A2KDM4EMAPTMEN1KMT2A | |
| SCHEMBL21160841 | 0.84 | CYP1A2 (0.71) | CYP1A2KDM4EMAPTMEN1KMT2A | |
| SCHEMBL15827402 | 0.80 | KDM4E (0.58) | CYP1A2KDM4EMAPTTDP1ALDH1A1 | |
| SCHEMBL12913709 | 0.75 | VDR (0.43) | CYP1A2KDM4EMAPTMEN1KMT2A | |
| SCHEMBL12913705 | 0.74 | VDR (0.45) | CYP1A2KDM4EMAPTMEN1KMT2A | |
| SCHEMBL21160629 | 0.73 | MAPT (0.48) | CYP1A2KDM4EMAPTCYP2C19 | |
| SCHEMBL21160631 | 0.73 | HTR1A (0.41) | CYP1A2KDM4EMAPTMEN1KMT2A | |
| SCHEMBL21160628 | 0.72 | CYP1A2 (0.38) | CYP1A2KDM4EMAPT | |
| SCHEMBL21160837 | 0.70 | CYP1A2 (0.38) | CYP1A2KDM4EMAPTMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11215928-B2 | Composition for resist underlayer film formation, resist underlayer film and method for forming the same, and production method of a patterned substrate | JSR CORPORATION (JP) | 2022-01-04 | — | — | US | disclosed |
| US-20190212650-A1 | COMPOSITION FOR RESIST UNDERLAYER FILM FORMATION, RESIST UNDERLAYER FILM AND METHOD FOR FORMING THE SAME, AND PRODUCTION METHOD OF A PATTERNED SUBSTRATE | JSR CORPORATION (JP) | 2019-07-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11215928-B2 | Composition for resist underlayer film formation, resist underlayer film and method for forming the same, and production method of a patterned substrate | TOP1, OXA1L, RER1 | CYP1A2 273/4885KDM4E 1890/4885MAPT 3830/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.